Twice-per-weekSelinexor, 2 Days Melphalan

Clinical trial NCT06613035 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06613035
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2024-09-30
Primary completion: 2027-09-30
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.